Erasca, Inc. (ERAS) vs Iovance Biotherapeutics, Inc. (IOVA)

Erasca, Inc. and Iovance Biotherapeutics, Inc. are both Biotechnology companies. Erasca, Inc. and Iovance Biotherapeutics, Inc. are of similar size ($5.1B and $4.9B). Erasca, Inc. has the higher net margin (0.00% vs −89.1%) and the lower return on invested capital (−203.1% vs −43.0%). Across the 13 metrics below, Iovance Biotherapeutics, Inc. leads on 7 and Erasca, Inc. on 6.

Valuation

Metric ERAS IOVA Biotechnology median
P/E n/m n/m 7.88
P/S n/m 15.24 11.47
P/B 12.26 6.73 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales n/m 14.33 10.73
Earnings yield (6.67%) (6.64%) (28.84%)
Free cash flow yield (5.68%) (5.99%) (23.03%)

Profitability

Metric ERAS IOVA Biotechnology median
Gross margin 0.00% 48.40% 65.16%
Operating margin 0.00% (92.72%) 0.00%
Net margin 0.00% (89.09%) 0.00%
Free cash flow margin 0.00% (91.21%) 0.00%
Return on equity (78.25%) (40.36%) (57.72%)
Return on assets (65.25%) (31.76%) (49.22%)
Return on invested capital (203.13%) (42.96%) 0.00%

Growth

Metric ERAS IOVA Biotechnology median
Revenue growth (TTM) — 34.55% 5.64%
EPS growth (last fiscal year) 36.23% 14.84% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ERAS IOVA Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 8.29 4.35 4.73
Net debt to EBITDA 1.93 0.82 0.96

Dividend

Metric ERAS IOVA Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ERAS IOVA Biotechnology median
Market cap 5.08b 4.90b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack